SURVYR

NVAX

Novavax, Inc.
$10.02
+$0.62 (6.60%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-29%-8%+13%+33%+54%Oct 2025Oct 2026Apr 202652w high $13.3952w low $6.20
NVAXSPY
Wall St. Highest PT $25.00 (+149.5%) Wall St. Avg PT $14.22 (+41.9%)
$6$11$16$21$26POC $9Hi $25Avg $14
Underwater Drawdown %Max DD -34.6%Current -21.8%
0.0%-34.6%
Relative Strength vs SPY+1.6% vs SPYOutperforming
+39%0%-39%
1W
−$1.41 (12.34%)
1M
−$0.61 (5.74%)
3M
+$2.65 (35.96%)
6M
+$2.10 (26.52%)
YTD
+$3.30 (49.11%)
1Y
+$1.32 (15.17%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
9 analysts · mean score 2.33
1 = Strong Buy · 5 = Sell
Strong Buy00%
Buy556%
Hold111%
Underperform111%
Sell222%
Wall Street consensus
Analyst price targets
Current price$10.02
Average target$14.22
+$4.20 (+41.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$7.00
Median$16.00
High$25.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-15 · Citigroup reiterated Sell on NVAX
Reiterated
2026-06-11 · BTIG reiterated Buy on NVAX
Reiterated
2026-05-06 · TD Cowen reiterated Hold on NVAX
Reiterated
2026-02-27 · HC Wainwright & Co. reiterated Buy on NVAX
Reiterated
2026-01-20 · BTIG reiterated Buy on NVAX
Reiterated
2025-11-18 · JP Morgan reiterated Underweight on NVAX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.7B
P/E (next 12 months, estimated)-61.1
52-week range$6.20 – $13.39
Revenue growth (latest quarter vs a year ago)-76.3%
Dividend yieldNo dividend
Analyst consensusBuy (9)
Average analyst price target$14.22 (+42%)

What they do

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for NVAX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

NVAX earningsNext report in 8 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Before the open
EPS consensus-$0.42 range -$0.42–-$0.42
Revenue consensus$54.2M 7 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.32est -$0.38+16.6%Above estimates
May 6, 2026-$0.06est -$0.37+83.8%Above estimates
Feb 26, 2026$0.11est -$0.55+120.2%Above estimates
Nov 6, 2025-$0.47est -$1.13+58.0%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-27 18:04:19 ET
24-1125-0225-0525-0825-1126-0226-0526-08-1.132.93
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$56.7M-76.3%
2026-03-31$139.5M–
2025-12-31$147.1M–
2025-09-30$70.4M–
2025-06-30$239.2M–

News & catalysts

More news
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports
Motley Fool · Oct 22
3 Reasons NVAX is Risky and 1 Stock to Buy Instead
StockStory · Oct 20
Moderna Stock Slumps, but It’s Too Early to Panic
Barrons.com · Oct 16
Rating changes
Reiterated
2026-10-15 · Citigroup reiterated Sell on NVAX
Reiterated
2026-06-11 · BTIG reiterated Buy on NVAX
Reiterated
2026-05-06 · TD Cowen reiterated Hold on NVAX
Reiterated
2026-02-27 · HC Wainwright & Co. reiterated Buy on NVAX
Reiterated
2026-01-20 · BTIG reiterated Buy on NVAX
Reiterated
2025-11-18 · JP Morgan reiterated Underweight on NVAX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-27 18:04:19 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026